Step 1
 [HumanMessage(content='What is the mechanism of action for Cetuximab and which receptor does it target?', additional_kwargs={}, response_metadata={}, id='2f199225-4621-4caf-a8fa-27a519ef417b')]

Step 2
 [HumanMessage(content='What is the mechanism of action for Cetuximab and which receptor does it target?', additional_kwargs={}, response_metadata={}, id='2f199225-4621-4caf-a8fa-27a519ef417b'), FunctionMessage(content="{'status': 'success', 'data': [{'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Complement C1q subcomponent subunit A'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Complement C1q subcomponent subunit B'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Complement C1q subcomponent subunit C'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Epidermal growth factor receptor'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'High affinity immunoglobulin gamma Fc receptor I'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Low affinity immunoglobulin gamma Fc region receptor II-a'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Low affinity immunoglobulin gamma Fc region receptor III-A'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Low affinity immunoglobulin gamma Fc region receptor III-B'}]}", additional_kwargs={'idx': 1, 'args': {'problem': 'What is the mechanism of action for Cetuximab and which receptor does it target?'}}, response_metadata={}, name='text2SQL', id='af54733e-c4c9-4d26-8a18-39040c90c0b2'), FunctionMessage(content='join', additional_kwargs={'idx': 2, 'args': ()}, response_metadata={}, name='join', id='cb2dc3d1-9b7d-4e8b-8d79-37ee6e3c8ff9')]

Step 3
 [HumanMessage(content='What is the mechanism of action for Cetuximab and which receptor does it target?', additional_kwargs={}, response_metadata={}, id='2f199225-4621-4caf-a8fa-27a519ef417b'), FunctionMessage(content="{'status': 'success', 'data': [{'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Complement C1q subcomponent subunit A'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Complement C1q subcomponent subunit B'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Complement C1q subcomponent subunit C'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Epidermal growth factor receptor'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'High affinity immunoglobulin gamma Fc receptor I'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Low affinity immunoglobulin gamma Fc region receptor II-a'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Low affinity immunoglobulin gamma Fc region receptor III-A'}, {'mechanism_of_action': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.', 'receptor_targeted': 'Low affinity immunoglobulin gamma Fc region receptor III-B'}]}", additional_kwargs={'idx': 1, 'args': {'problem': 'What is the mechanism of action for Cetuximab and which receptor does it target?'}}, response_metadata={}, name='text2SQL', id='af54733e-c4c9-4d26-8a18-39040c90c0b2'), FunctionMessage(content='join', additional_kwargs={'idx': 2, 'args': ()}, response_metadata={}, name='join', id='cb2dc3d1-9b7d-4e8b-8d79-37ee6e3c8ff9'), AIMessage(content='Thought: The mechanism of action for Cetuximab is clearly described, and the primary receptor it targets is the Epidermal Growth Factor Receptor (EGFr). The other receptors listed are not relevant to the primary action of Cetuximab.', additional_kwargs={}, response_metadata={}, id='4842399e-02ae-4673-b391-299faa8b1dcb'), AIMessage(content="{'Summary': 'Cetuximab targets the Epidermal Growth Factor Receptor (EGFr).','details': 'Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.','source': 'Data obtained from the executed plan results.','inference': 'Epidermal Growth Factor Receptor (EGFr)','extra explanation': 'The other receptors listed are not relevant to the primary action of Cetuximab.'}", additional_kwargs={}, response_metadata={}, id='508a0f27-e65c-45c0-a7c6-0f7dd3e145e9')]


